Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism

Ryusei Sugimoto, Hiroshi Watanabe, Komei Ikegami, Yuki Enoki, Tadashi Imafuku, Yoshiaki Sakaguchi, Michiya Murata, Kento Nishida, Shigeyuki Miyamura, Yu Ishima, Motoko Tanaka, Kazutaka Matsushita, Hirotaka Komaba, Masafumi Fukagawa, Masaki Otagiri, Toru Maruyama

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hyperuricemia occurs with increasing frequency among patients with hyperparathyroidism. However, the molecular mechanism by which the serum parathyroid hormone (PTH) affects serum urate levels remains unknown. This was studied in uremic rats with secondary hyperparathyroidism where serum urate levels were found to be increased and urate excretion in the intestine and kidney decreased, presumably due to down-regulation of the expression of the urate exporter ABCG2 in intestinal and renal epithelial membranes. These effects were prevented by administration of the calcimimetic cinacalcet, a PTH suppressor, suggesting that PTH may down-regulate ABCG2 expression. This was directly tested in intestinal Caco-2 cells where the expression of ABCG2 on the plasma membrane was down-regulated by PTH (1-34) while its mRNA level remained unchanged. Interestingly, an inactive PTH derivative (13-34) had no effect, suggesting that a posttranscriptional regulatory system acts through the PTH receptor to regulate ABCG2 plasma membrane expression. As found in an animal study, additional clinical investigations showed that treatment with cinacalcet resulted in significant reductions in serum urate levels together with decreases in PTH levels in patients with secondary hyperparathyroidism undergoing dialysis. Thus, PTH down-regulates ABCG2 expression on the plasma membrane to suppress intestinal and renal urate excretion, and the effects of PTH can be prevented by cinacalcet treatment.

Original languageEnglish
Pages (from-to)658-670
Number of pages13
JournalKidney International
Volume91
Issue number3
DOIs
Publication statusPublished - 2017 Mar 1
Externally publishedYes

Fingerprint

Secondary Hyperparathyroidism
Uric Acid
Parathyroid Hormone
Down-Regulation
Cell Membrane
Serum
Parathyroid Hormone Receptor Type 1
Kidney
Hyperuricemia
Caco-2 Cells
Hyperparathyroidism
Intestines
Dialysis
Messenger RNA
Membranes
Therapeutics

Keywords

  • ABCG2
  • chronic kidney disease
  • parathyroid hormone
  • secondary hyperparathyroidism
  • urate

ASJC Scopus subject areas

  • Nephrology

Cite this

Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. / Sugimoto, Ryusei; Watanabe, Hiroshi; Ikegami, Komei; Enoki, Yuki; Imafuku, Tadashi; Sakaguchi, Yoshiaki; Murata, Michiya; Nishida, Kento; Miyamura, Shigeyuki; Ishima, Yu; Tanaka, Motoko; Matsushita, Kazutaka; Komaba, Hirotaka; Fukagawa, Masafumi; Otagiri, Masaki; Maruyama, Toru.

In: Kidney International, Vol. 91, No. 3, 01.03.2017, p. 658-670.

Research output: Contribution to journalArticle

Sugimoto, R, Watanabe, H, Ikegami, K, Enoki, Y, Imafuku, T, Sakaguchi, Y, Murata, M, Nishida, K, Miyamura, S, Ishima, Y, Tanaka, M, Matsushita, K, Komaba, H, Fukagawa, M, Otagiri, M & Maruyama, T 2017, 'Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism', Kidney International, vol. 91, no. 3, pp. 658-670. https://doi.org/10.1016/j.kint.2016.09.041
Sugimoto, Ryusei ; Watanabe, Hiroshi ; Ikegami, Komei ; Enoki, Yuki ; Imafuku, Tadashi ; Sakaguchi, Yoshiaki ; Murata, Michiya ; Nishida, Kento ; Miyamura, Shigeyuki ; Ishima, Yu ; Tanaka, Motoko ; Matsushita, Kazutaka ; Komaba, Hirotaka ; Fukagawa, Masafumi ; Otagiri, Masaki ; Maruyama, Toru. / Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. In: Kidney International. 2017 ; Vol. 91, No. 3. pp. 658-670.
@article{60cc50583059438383e657147b07cea1,
title = "Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism",
abstract = "Hyperuricemia occurs with increasing frequency among patients with hyperparathyroidism. However, the molecular mechanism by which the serum parathyroid hormone (PTH) affects serum urate levels remains unknown. This was studied in uremic rats with secondary hyperparathyroidism where serum urate levels were found to be increased and urate excretion in the intestine and kidney decreased, presumably due to down-regulation of the expression of the urate exporter ABCG2 in intestinal and renal epithelial membranes. These effects were prevented by administration of the calcimimetic cinacalcet, a PTH suppressor, suggesting that PTH may down-regulate ABCG2 expression. This was directly tested in intestinal Caco-2 cells where the expression of ABCG2 on the plasma membrane was down-regulated by PTH (1-34) while its mRNA level remained unchanged. Interestingly, an inactive PTH derivative (13-34) had no effect, suggesting that a posttranscriptional regulatory system acts through the PTH receptor to regulate ABCG2 plasma membrane expression. As found in an animal study, additional clinical investigations showed that treatment with cinacalcet resulted in significant reductions in serum urate levels together with decreases in PTH levels in patients with secondary hyperparathyroidism undergoing dialysis. Thus, PTH down-regulates ABCG2 expression on the plasma membrane to suppress intestinal and renal urate excretion, and the effects of PTH can be prevented by cinacalcet treatment.",
keywords = "ABCG2, chronic kidney disease, parathyroid hormone, secondary hyperparathyroidism, urate",
author = "Ryusei Sugimoto and Hiroshi Watanabe and Komei Ikegami and Yuki Enoki and Tadashi Imafuku and Yoshiaki Sakaguchi and Michiya Murata and Kento Nishida and Shigeyuki Miyamura and Yu Ishima and Motoko Tanaka and Kazutaka Matsushita and Hirotaka Komaba and Masafumi Fukagawa and Masaki Otagiri and Toru Maruyama",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.kint.2016.09.041",
language = "English",
volume = "91",
pages = "658--670",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism

AU - Sugimoto, Ryusei

AU - Watanabe, Hiroshi

AU - Ikegami, Komei

AU - Enoki, Yuki

AU - Imafuku, Tadashi

AU - Sakaguchi, Yoshiaki

AU - Murata, Michiya

AU - Nishida, Kento

AU - Miyamura, Shigeyuki

AU - Ishima, Yu

AU - Tanaka, Motoko

AU - Matsushita, Kazutaka

AU - Komaba, Hirotaka

AU - Fukagawa, Masafumi

AU - Otagiri, Masaki

AU - Maruyama, Toru

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Hyperuricemia occurs with increasing frequency among patients with hyperparathyroidism. However, the molecular mechanism by which the serum parathyroid hormone (PTH) affects serum urate levels remains unknown. This was studied in uremic rats with secondary hyperparathyroidism where serum urate levels were found to be increased and urate excretion in the intestine and kidney decreased, presumably due to down-regulation of the expression of the urate exporter ABCG2 in intestinal and renal epithelial membranes. These effects were prevented by administration of the calcimimetic cinacalcet, a PTH suppressor, suggesting that PTH may down-regulate ABCG2 expression. This was directly tested in intestinal Caco-2 cells where the expression of ABCG2 on the plasma membrane was down-regulated by PTH (1-34) while its mRNA level remained unchanged. Interestingly, an inactive PTH derivative (13-34) had no effect, suggesting that a posttranscriptional regulatory system acts through the PTH receptor to regulate ABCG2 plasma membrane expression. As found in an animal study, additional clinical investigations showed that treatment with cinacalcet resulted in significant reductions in serum urate levels together with decreases in PTH levels in patients with secondary hyperparathyroidism undergoing dialysis. Thus, PTH down-regulates ABCG2 expression on the plasma membrane to suppress intestinal and renal urate excretion, and the effects of PTH can be prevented by cinacalcet treatment.

AB - Hyperuricemia occurs with increasing frequency among patients with hyperparathyroidism. However, the molecular mechanism by which the serum parathyroid hormone (PTH) affects serum urate levels remains unknown. This was studied in uremic rats with secondary hyperparathyroidism where serum urate levels were found to be increased and urate excretion in the intestine and kidney decreased, presumably due to down-regulation of the expression of the urate exporter ABCG2 in intestinal and renal epithelial membranes. These effects were prevented by administration of the calcimimetic cinacalcet, a PTH suppressor, suggesting that PTH may down-regulate ABCG2 expression. This was directly tested in intestinal Caco-2 cells where the expression of ABCG2 on the plasma membrane was down-regulated by PTH (1-34) while its mRNA level remained unchanged. Interestingly, an inactive PTH derivative (13-34) had no effect, suggesting that a posttranscriptional regulatory system acts through the PTH receptor to regulate ABCG2 plasma membrane expression. As found in an animal study, additional clinical investigations showed that treatment with cinacalcet resulted in significant reductions in serum urate levels together with decreases in PTH levels in patients with secondary hyperparathyroidism undergoing dialysis. Thus, PTH down-regulates ABCG2 expression on the plasma membrane to suppress intestinal and renal urate excretion, and the effects of PTH can be prevented by cinacalcet treatment.

KW - ABCG2

KW - chronic kidney disease

KW - parathyroid hormone

KW - secondary hyperparathyroidism

KW - urate

UR - http://www.scopus.com/inward/record.url?scp=85008450574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008450574&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2016.09.041

DO - 10.1016/j.kint.2016.09.041

M3 - Article

C2 - 27988213

AN - SCOPUS:85008450574

VL - 91

SP - 658

EP - 670

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -